TIGIT and melanoma: Cancer testis antigen NY-ESO-1-specific CD8+T cell responses are increased by the addition of blocking mAbs against TIGIT and/or PD-1 when peripheral blood mononuclear cells (PBMCs) from melanoma patients are stimulated with NY-ESO-1157–165 peptide.